Literature DB >> 12761039

Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.

N A Alam1, A J Rowan, N C Wortham, P J Pollard, M Mitchell, J P Tyrer, E Barclay, E Calonje, S Manek, S J Adams, P W Bowers, N P Burrows, R Charles-Holmes, L J Cook, B M Daly, G P Ford, L C Fuller, S E Hadfield-Jones, N Hardwick, A S Highet, M Keefe, S P MacDonald-Hull, E D A Potts, M Crone, S Wilkinson, F Camacho-Martinez, S Jablonska, R Ratnavel, A MacDonald, R J Mann, K Grice, G Guillet, M S Lewis-Jones, H McGrath, D C Seukeran, P J Morrison, S Fleming, S Rahman, D Kelsell, I Leigh, S Olpin, I P M Tomlinson.   

Abstract

Germline mutations of the fumarate hydratase (FH, fumarase) gene are found in the recessive FH deficiency syndrome and in dominantly inherited susceptibility to multiple cutaneous and uterine leiomyomatosis (MCUL). We have previously reported a number of germline FH mutations from MCUL patients. In this study, we report additional FH mutations in MCUL and FH deficiency patients. Mutations can readily be found in about 75% of MCUL cases and most cases of FH deficiency. Some of the more common FH mutations are probably derived from founding individuals. Protein-truncating FH mutations are functionally null alleles. Disease-associated missense FH changes map to highly conserved residues, mostly in or around the enzyme's active site or activation site; we predict that these mutations severely compromise enzyme function. The mutation spectra in FH deficiency and MCUL are similar, although in the latter mutations tend to occur earlier in the gene and, perhaps, are more likely to result in a truncated or absent protein. We have found that not all mutation-carrier parents of FH deficiency children have a strong predisposition to leiomyomata. We have confirmed that renal carcinoma is sometimes part of MCUL, as part of the variant hereditary leiomyomatosis and renal cancer (HLRCC) syndrome, and have shown that these cancers may have either type II papillary or collecting duct morphology. We have found no association between the type or site of FH mutation and any aspect of the MCUL phenotype. Biochemical assay for reduced FH functional activity in the germline of MCUL patients can indicate carriers of FH mutations with high sensitivity and specificity, and can detect reduced FH activity in some patients without detectable FH mutations. We conclude that MCUL is probably a genetically homogeneous tumour predisposition syndrome, primarily resulting from absent or severely reduced fumarase activity, with currently unknown functional consequences for the smooth muscle or kidney cell.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761039     DOI: 10.1093/hmg/ddg148

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  83 in total

1.  Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.

Authors:  Zehra Ordulu; Paola Dal Cin; Wilson W S Chong; Kwong Wai Choy; Charles Lee; Michael G Muto; Bradley J Quade; Cynthia C Morton
Journal:  Genes Chromosomes Cancer       Date:  2010-12       Impact factor: 5.006

2.  Incidental diagnosis of HLRCC following investigation for Asperger Syndrome: actionable and actioned.

Authors:  Bich-Thu Duong; Ravi Savarirayan; Ingrid Winship
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

3.  Increased risk of cancer in patients with fumarate hydratase germline mutation.

Authors:  H J Lehtonen; M Kiuru; S K Ylisaukko-Oja; R Salovaara; R Herva; P A Koivisto; O Vierimaa; K Aittomäki; E Pukkala; V Launonen; L A Aaltonen
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

4.  The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters.

Authors:  Karen L Huyck; Carolien I M Panhuysen; Karen T Cuenco; Jingmei Zhang; Hilary Goldhammer; Emlyn S Jones; Priya Somasundaram; Allison M Lynch; Bernard L Harlow; Hang Lee; Elizabeth A Stewart; Cynthia C Morton
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

Review 5.  Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis.

Authors:  Markku Miettinen
Journal:  Mod Pathol       Date:  2014-01       Impact factor: 7.842

6.  Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma.

Authors:  Cathy D Vocke; Christopher J Ricketts; Maria J Merino; Ramaprasad Srinivasan; Adam R Metwalli; Lindsay A Middelton; James Peterson; Youfeng Yang; W Marston Linehan
Journal:  Genes Chromosomes Cancer       Date:  2017-03-31       Impact factor: 5.006

7.  Hereditary leiomyomatosis and renal cell cancer syndrome: identification and clinical characterization of a novel mutation in the FH gene in a Colombian family.

Authors:  Carolina Arenas Valencia; Martha Lucia Rodríguez López; Andrea Yimena Cardona Barreto; Edgar Garavito Rodríguez; Clara Eugenia Arteaga Díaz
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

8.  Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient.

Authors:  Ismail Alrashdi; Samantha Levine; Joan Paterson; Rohit Saxena; Soonie R Patel; Sarita Depani; Darren R Hargrave; Kathy Pritchard-Jones; Shirley V Hodgson
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

9.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.

Authors:  Youfeng Yang; Vladimir A Valera; Hesed M Padilla-Nash; Carole Sourbier; Cathy D Vocke; Manish A Vira; Mones S Abu-Asab; Gennady Bratslavsky; Maria Tsokos; Maria J Merino; Peter A Pinto; Ramaprasad Srinivasan; Thomas Ried; Len Neckers; W Marston Linehan
Journal:  Cancer Genet Cytogenet       Date:  2010-01-01

10.  Cancer as a metabolic disease.

Authors:  Thomas N Seyfried; Laura M Shelton
Journal:  Nutr Metab (Lond)       Date:  2010-01-27       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.